The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Monday is going to be very interesting but it does indeed look like Medusa are developing another test that is further along than Avacta
Yes very strange. It describes it as a test to check if you HAVE covid not HAD. Anyway; long weekend of speculation ahead lol
@JoeyDiamond
I think you've got your wish.
Dummy press releases used all the time, stick some figures in so we can test format, update when figures in, especially at launch, other wise you
End up trying to covert pages of Latin. They might be true or not, either way can’t be trusted.
Yes someone might lose their job but is likely to be a a developer filling in for ops who are on holiday. Stuff like this happens all the time, normally it’s a hic up.
Expect to see something from al on Monday. True or not it needs to be clarified.
I guess he doesn’t have to say anything as the figures weren’t under AVACTA but a separate paragraph and a separate company ?
This is an antibody test developed in Spain, not Avacta's
His brand all over it, yep needs to say something. Affects share price and it’s a contractual partner
Just my 2p, no idea of regulations truth be told
https://pubmed.ncbi.nlm.nih.gov/32355546/
A saliva version of that antibody test... can’t find anything on t’internet about one. Looks like that’s what they’re also going to flog under their brand. Good for them. Sir Al decided it wasn’t a market worth going after.
Yes it seems to have a number of contradictions.... very confusing ! I’m of the view that this is a dummy run so I’m not going to take the figures quoted too seriously. Nice to see some activity though ... but I really hope they do a better job with the final version when it’s ready !!!
@PL
It doesn't match up:
Conclusions: The colloidal gold immunochromatography assay for SARS-Cov-2 specific IgM/IgG anti-body had 71.1% sensitivity and 96.2% specificity in this population, showing the potential for a useful rapid diagnosis test for COVID-19. Further investigations should be done to evaluate this assay in variety of clinical settings and populations.
It’s possible the numbers are placeholders, I’m going from my (fairly extensive!) direct experience. You wouldn’t need to convert the ‘Latin’. You’d only use that for setting up a template/style sheet - which is why I’m saying It’s more likely to be the real thing (at least everything except the numbers) In favour of the argument that the numbers could be placeholders is that whoever is writing the copy may not have been given that information as yet.
Why would it ‘match up’? It’s not Avacta!
If the UK government is planning to take the lion’s share of BBI’s production capacity perhaps Medusa will have to offer other tests as well as Avacta?
I would also say, that I have worked with loads of terrible, sloppy, careless developers, so it’s just as likely to be their regular person who has messed up!
Still, looks and feels genuine to me though.
If it's some other test then shafted or a cute move ???
I think it’s fair to say that I’ve been talking rubbish and there are two tests, our one, and an antibody test that medusa are developing separately.
scarratwho- what are you going on about no offense but did you even read the page ?
This is a separate test, nothing to do with Avacta. An antibody test coming out of Spain I believe.
So there you have it. There are now two rapid tests and one is further ahead than Avacta's by the looks of it
Please remember avacta is not an antibody test, so it doesn’t matter how far ahead this separate test is.
DaDooRonRon - or perhaps Medusa will be selling more than one Avacta test but under different brand names/packaging. There may be options available depending on what mix of Sensitivity / Specificity you prefer ????
My reading of this, is Medusa19 are going to be suppliers of multiple types of tests...
Whether or not it’s good news for Avacta, will now depending on quality& price versus other products Medusa supply.
If we find ourselves too expensive or lower on quality than the others, then it’s BAD news... as they are our only route to the consumer market.
The opposite is also true though.
I didn’t say it matched, that paper was using a blood sample. The test on that ropey website suggested saliva, but I can’t find that test on t’internet.
Yes why sell one test when you can get double the sales revenue from two? Do you want the ‘Have I got it test.’ or the ‘Have I had it test’? Or both?
Ahem,
Chengdo
Message from granny. She says she is a wonderful egg sucker. Apparantly she used to practice all the time on my grandad's b alls.
Thanks anyway. lol
https://medusa19.com/
Medusa 19 are working with their partner, Medusa 19 Life Sciences, to exclusively bring to market the best in class saliva lateral flow test for early indication of SARS-CoV-2 proteins and highly accurate in identifying the virus in asymptomatic patients.
The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating infection from SARS-CoV-2, the virus underlying COVID-19.
It is a lateral flow test requiring a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 10 minutes.
Comparable results with a PCR test for asymptomatic patients but without significant discomfort from throat and nasal swab and considerable delay in results.
94% sensitivity, 95% specificity and 95% accurate
Why do people just copy and paste stuff like this that everyone can read / has read? They do it with RNS’s too.. what’s the point?